How Can Access to PCSK9 Inhibitors be Improved?

Mark Tesell, PharmD, BCPS, clinical consultant pharmacist for UMass Medical School Clinical Pharmacy Services, discusses potential solutions for access to cholesterol lowering drugs to improve.

Related Content:

InterviewsSpecialty Pharmacy

Treatment with Ofatumumab Increases Number of Patients Who Achieve No Evidence of Disease Activity for MS

Bringing Oncology Pharmacy Leaders, Payers Together to Address Unmet Educational Needs in the Field

Oncology Overview: Sonidegib (Odomzo) for Locally Advanced Basal Cell Carcinoma